Potential markers of prostate cancer in urine

Zdobinsk T, Vesel . Potenciln markery karcinomu prostaty v moi. Karcinom prostaty je jednm z nejastjch onkologickch onemocnn mu ve svt. Diagnostika a stratifikace pacient jsou klov pro zajitn vasn a adekvtn terapie. Souasn standardy se opraj pevn o PSA, jeho ndorov specificita je limitovna. Tento pehled se zamuje na neinvazivn potenciln onkomarkery zskan z moi vetn oxidanho stresu, metabolomiky a analzy nukleovch kyselin. V rmci nkterch studi se ukazuje, e zven hladiny marker jako F2-isoprostanza, sarcosin a PCA3 mohou indikovat ptomnost a agresivitu karcinomu prostaty. Nov kombinovan testy Prostarix, Mi-Prostate Score, SelectMDX nebo ExoDX nabzej potencil pro zlepen stratifikace pacient a snen potu negativnch biopsi. Klinick vyuit tchto novch marker je zatm omezen. Vzhledem k heterogenit tohoto onemocnn je nezbytn pokraovat ve vzkumu, kter usnadn personalizovan pstup v lb.

Authors

Publication Details

Journal
Czech Urology
Published
2024-12-18
DOI
https://doi.org/10.48095/cccu2024030
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Potential markers of prostate cancer in urine

Štěpán Veselý, Tereza Zdobinská
Czech Urology
Prostate Cancer Treatment and Research
article

Potential markers of prostate cancer in urine

Štěpán Veselý, Tereza Zdobinská
article en

Abstract

Zdobinsk T, Vesel . Potenciln markery karcinomu prostaty v moi. Karcinom prostaty je jednm z nejastjch onkologickch onemocnn mu ve svt. Diagnostika a stratifikace pacient jsou klov pro zajitn vasn a adekvtn terapie. Souasn standardy se opraj pevn o PSA, jeho ndorov specificita je limitovna. Tento pehled se zamuje na neinvazivn potenciln onkomarkery zskan z moi vetn oxidanho stresu, metabolomiky a analzy nukleovch kyselin. V rmci nkterch studi se ukazuje, e zven hladiny marker jako F2-isoprostanza, sarcosin a PCA3 mohou indikovat ptomnost a agresivitu karcinomu prostaty. Nov kombinovan testy Prostarix, Mi-Prostate Score, SelectMDX nebo ExoDX nabzej potencil pro zlepen stratifikace pacient a snen potu negativnch biopsi. Klinick vyuit tchto novch marker je zatm omezen. Vzhledem k heterogenit tohoto onemocnn je nezbytn pokraovat ve vzkumu, kter usnadn personalizovan pstup v lb.

Czech UrologyVol. 28(4)
Good health and well-being
Openalex Percentile: Top 55%
Prostate Cancer Treatment and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.